CURAGEN CORP
10-Q, EX-27, 2000-11-07
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: CURAGEN CORP, 10-Q, EX-11, 2000-11-07
Next: CURAGEN CORP, 424B5, 2000-11-07



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                     244,556,268
<SECURITIES>                                         0
<RECEIVABLES>                                  867,942
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                           246,763,139
<PP&E>                                      24,206,351
<DEPRECIATION>                              10,228,387
<TOTAL-ASSETS>                             266,056,518
<CURRENT-LIABILITIES>                       11,411,343
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       372,326
<OTHER-SE>                                  82,806,758
<TOTAL-LIABILITY-AND-EQUITY>               266,056,518
<SALES>                                              0
<TOTAL-REVENUES>                            15,619,770
<CGS>                                                0
<TOTAL-COSTS>                               27,702,643
<OTHER-EXPENSES>                             9,574,280
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                           (18,927,158)
<INCOME-TAX>                                   620,000
<INCOME-CONTINUING>                       (18,371,628)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (18,371,628)
<EPS-BASIC>                                     (0.49)
<EPS-DILUTED>                                   (0.49)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission